Neil F. McFarlane
CIK 1681098 · President and CEO · last filed 2026-02-10
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$6.79M
Companies
4
Total Filings
26
Lifetime Open-Market Net
-$2.47M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ZVRA | President and CEO | 401,850 | $12.65 | $5.08M | -$1.92M | 8 | 2026-02-10 |
| COLL | Director | 49,365 | $34.64 | $1.71M | $0 | 4 | 2024-05-16 |
| Adamas Pharmaceuticals Inc (ADMS) Delisted | Chief Executive Officer | 0 | $8.22 | $0 | $0 | 4 | 2021-11-24 |
| Travere Therapeutics, Inc. (RTRX) Delisted | Chief Operating Officer | 27,972 | — | — | -$552.6K | 10 | 2019-05-16 |
Recent Filings · Page 2 of 3
26 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-05-23 | COLL | Grant (A) | +14,035 | $0 | EDGAR |
| 2022-04-08 | COLL | Grant (A) | +17,845 | $0 | EDGAR |
| 2021-11-24 | Adamas Pharmaceuticals Inc (ADMS) Delisted | Mixed | −525,000 | $0 | EDGAR |
| 2021-03-03 | Adamas Pharmaceuticals Inc (ADMS) Delisted | Grant (A) | +300,000 | $0 | EDGAR |
| 2020-03-20 | Adamas Pharmaceuticals Inc (ADMS) Delisted | Grant (A) | +100,000 | $0 | EDGAR |
| 2019-09-17 | Adamas Pharmaceuticals Inc (ADMS) Delisted | Grant (A) | +125,000 | $0 | EDGAR |
| 2019-05-16 | Travere Therapeutics, Inc. (RTRX) Delisted | Sell (S) | −1,968 | -$35.9K | EDGAR |
| 2018-12-21 | Travere Therapeutics, Inc. (RTRX) Delisted | Sell (S) | −11,125 | -$248.3K | EDGAR |
| 2018-12-20 | Travere Therapeutics, Inc. (RTRX) Delisted | Grant (A) | +11,125 | $0 | EDGAR |
| 2018-11-16 | Travere Therapeutics, Inc. (RTRX) Delisted | Sell (S) | −10,000 | -$237.3K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.